This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 4441299 results found since Jan 2013.

Multifocal enlargement and increased vascularization of peripheral nerves detected by sonography in CIDP: A pilot study
Conclusion: Multiple nerve enlargements occur in CIDP showing a relation with a lower MRC sum-score, increased nerve vascularization and a higher total protein of the CSF.Significance: Our findings of nerve enlargement and increased nerve vascularization may be tools to monitor disease activity in CIDP, but further studies are needed.
Source: Clinical Neurophysiology - July 22, 2013 Category: Neuroscience Authors: H.S. Goedee, G.J.F. Brekelmans, L.H. Visser Tags: Motor Neurone and Neuromuscular Diseases Source Type: research

NADPH Oxidases (NOX) Enzymes Induced Oxidative Stress in CIDP Patients (P1.070)
ConclusionsShort-term immune therapies are effective in CIDP, but clinical and pathological variability accounts for diagnostic problems and up to one third of cases lack of sustained improvement. Our data suggest an involvement of NOX in ROS formation in CIDP patients. This hypothesis needs to be corroborated, by evaluating their role and eventually establishing markers to better identify patients and potentially effective therapies.Study supported by European Community's Framework Programme (FP7/2007-2013) under grant agreement n° 278611Disclosure: Dr. Calvo has nothing to disclose. Dr. Marrali has nothing to disclos...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Calvo, A., Marrali, G., Salamone, P., Casale, F., Cugnasco, P., Caorsi, C., Amoroso, A., Lopiano, L., Chio, A., Cocito, D. Tags: Neuromuscular Disease: Pathogenesis and Pathology Source Type: research

Corneal confocal microscopy detects small fiber damage in chronic inflammatory demyelinating polyneuropathy (CIDP)
Abstract Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune mediated peripheral neuropathy with multifocal involvement. Reliable biomarkers for diagnosis, disease progression and treatment response remain to be developed. We assessed the utility of corneal confocal microscopy (CCM) as a diagnostic marker for CIDP in 16 patients. CCM parameters including corneal nerve fiber density (NFD), nerve fiber length, number of main nerve trunks, number of nerve branches, nerve tortuosity, and dendritic cell density (DCD) were compared to those from 15 healthy controls and correlated with clinical and electroph...
Source: Journal of the Peripheral Nervous System - January 13, 2015 Category: Neurology Authors: Christian Schneider, Franziska Bucher, Claus Cursiefen, Gereon R. Fink, Ludwig M. Heindl, Helmar C. Lehmann Tags: Research Report Source Type: research

Effects of low frequency filtering on distal compound muscle action potential duration for diagnosis of CIDP: A Japanese-European multicenter prospective study.
CONCLUSIONS: Our results show that DCMAP duration is largely dependent on low frequency filter settings, but is a useful index for CIDP diagnosis when the cut-off values are properly determined at each filter setting. SIGNIFICANCE: Our data provide the systematic reference values of DCMAP duration for CIDP diagnosis available for most EMG laboratories. PMID: 25591830 [PubMed - as supplied by publisher]
Source: Clinical Neurophysiology - December 27, 2014 Category: Neurology Authors: Mitsuma S, Van den Bergh P, Rajabally YA, Van Parijs V, Martin-Lamb D, Sonoo M, Inaba A, Shimizu T, Isose S, Sato Y, Komori T, Misawa S, Kuwabara S, The Tokyo Metropolitan Neuromuscular Electrodiagnosis Study Group Tags: Clin Neurophysiol Source Type: research

Acute‐Onset chronic inflammatory demyelinating polyneuropathy. An electrodiagnostic study
Conclusion: Although several features might suggest the diagnosis of A‐CIDP at initial presentation, close follow up of GBS patients during the recovery phase is also needed for accurate diagnosis. EDX studies may distinguish patients with A‐CIDP from GBS patients. This article is protected by copyright. All rights reserved.
Source: Muscle and Nerve - March 26, 2015 Category: Internal Medicine Authors: Mohammad Anadani, Bashar Katirji Tags: Case of the Month Source Type: research

Retrospective Efficacy Evaluation Of Immunoglobulin Infusions (IVIG) In Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (P3.156)
CONCLUSIONS: This retrospective analysis confirms that some CIDP patients are "over-treated" and a number of them who remain stable can discontinue therapy without clinical worsening. Challenging the need for continuous IVIg treatment is a prudent approach in clinical practice. Study Supported by: CSL BehringDisclosure: Dr. Walsh has nothing to disclose. Dr. Dalakas has received personal compensation for activities with Baxter, Novartis, Grifols, CSL, Octapharma, Dysimmune Diseases Foundation, and Therapath. Dr. Dalakas has received personal compensation in an editorial capacity for Therapeutic Advances i Dr. Rakocevic has...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Walsh, A., Dalakas, M., Rakocevic, G. Tags: Neuromuscular Disease: Therapeutics Source Type: research

Acute‐onset chronic inflammatory demyelinating polyneuropathy: An electrodiagnostic study
Conclusion: Although several features may suggest the diagnosis of A‐CIDP at initial presentation, close follow‐up of GBS patients during the recovery phase is also needed for accurate diagnosis. EDx studies may distinguish patients with A‐CIDP from GBS patients. Muscle Nerve, 2015
Source: Muscle and Nerve - August 31, 2015 Category: Internal Medicine Authors: Mohammad Anadani, Bashar Katirji Tags: Case of the Month Source Type: research

Chronic inflammatory demyelinating polyneuropathy in children: a report of four patients with variable relapsing courses.
We present the cases of four pediatric patients diagnosed with CIDP to understand the variable clinical course of the disease in children. Our four patients were all between 8 and 12 years of age. Patients 1 and 2 were diagnosed with acute cerebellar ataxia or Guillain-Barré syndrome as initial symptoms. While patients 1 and 4 were given only intravenous dexamethasone (0.3 mg/kg/day) for 5 days at the first episode, Patients 2 and 3 were given a combination of intravenous immunoglobulin (2 g/kg) and dexamethasone (0.3 mg/kg/day). All patients were maintained with oral prednisolone at 30 mg/day, but their clinical courses ...
Source: Korean Journal of Pediatrics - November 19, 2015 Category: Pediatrics Tags: Korean J Pediatr Source Type: research

A potential 40% cost savings through treating cidp with tpe instead of ivig
Conclusions TPE is cheaper than IVIg for CIDP with respect to what is paid by DHB’s to the NZBS. It is unknown if similar cost savings exist in other healthcare systems. Potentially, IVIg may not need to be continued at full doses for an entire year and similarly TPE may not need to be continued at the same frequency. To address issues such as convenience of therapy and total patient care costs a prospective evaluation is needed. Furthermore, as there are no head-to-head IVIG-to-TPE studies in CIDP, the long-term efficacy of TPE in treating CIDP requires evaluation.
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 8, 2017 Category: Neurosurgery Authors: Parry, G. J., Buenz, E. J., Ranta, A. Tags: Abstracts Source Type: research

Nerve echogenicity and intranerve CSA variability in high-resolution nerve ultrasound (HRUS) in chronic inflammatory demyelinating polyneuropathy (CIDP)
ConclusionEchogenicity of the arm nerves in CIDP may be used as a prognostic marker, but not as a follow-up tool for evaluating clinical changes. Further studies in a larger cohort are needed to confirm these results.
Source: Journal of Neurology - December 15, 2018 Category: Neurology Source Type: research

Refractory CIDP with chronic lymphocytic leukaemia responding to chemoimmunotherapy.
We report a woman with severe refractory CIDP and coexisting chronic lymphocytic leukaemia (CLL) who improved dramatically after chemoimmunotherapy appropriate for the CLL, including rituximab. A subsequent CIDP relapse after 15 months responded again to similar treatment, and the improvement has been maintained with 3-monthly rituximab infusions as sole ongoing therapy. The case suggests that CIDP refractory to conventional treatment may have associated pathology, in this case haematological malignancy, and that treating the malignancy can effectively treat the CIDP. PMID: 33376152 [PubMed - as supplied by publisher]
Source: Practical Neurology - December 29, 2020 Category: Neurology Authors: Lewis D, Osman C, Allen D, Pinto AA, Duncombe A, Katifi HA Tags: Pract Neurol Source Type: research

French recommendations for the management of adult & amp; pediatric chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Rev Neurol (Paris). 2022 Sep 28:S0035-3787(22)00720-2. doi: 10.1016/j.neurol.2022.06.004. Online ahead of print.ABSTRACTChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare autoimmune disorder of the peripheral nervous system, primarily affecting the myelin sheath. The pathophysiology of CIDP is complex, involving both humoral and cellular immunity. The diagnosis of CIDP should be suspected in patients with symmetrical proximal and distal motor weakness and distal sensory symptoms of progressive onset, associated with decreased/abolished tendon reflexes. Treatments include intraveinous immunoglobulins...
Source: Revue Neurologique - October 1, 2022 Category: Neurology Authors: G Fargeot C Gitiaux L Magy Y Pereon E Delmont K Viala A Echaniz-Laguna Source Type: research

Undiagnosing CIDP (P02.231)
CONCLUSIONS: The number of demyelinating EDX abnormalities can decrease over time due to progression or improvement of the neuropathy. EDX studies at follow-up or at one time point may fail to confirm or identify the diagnosis of CIDP. Disclosure: Dr. Vo has nothing to disclose. Dr. Hanineva has nothing to disclose. Dr. Chin has received personal compensation for activities with Grifols Bioscience. Dr. Carey has nothing to disclose. Dr. Latov received personal compensation from Talecris, CSL Behring, Baxter, Novartis, Pfizer, and Elan for consulting services. Dr. Latov has equity interest in Therapath LLC. Dr. Langsdorf ha...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Vo, M., Hanineva, A., Chin, R., Carey, B., Latov, N., Langsdorf, J. Tags: P02 Clinical Neurophysiology: EMG Source Type: research

Heterogeneity of root and nerve ultrasound pattern in CIDP patients.
CONCLUSIONS: US may be of adjunctive diagnostic value in CIDP assessment. Nerve morphological changes may mirror the underlying pathophysiological mechanisms and seem to correlate with disease duration. SIGNIFICANCE: These results offer the possibility of exploring the use of US to assess CIDP disease activity and treatment. PMID: 24099922 [PubMed - as supplied by publisher]
Source: Clinical Neurophysiology - October 4, 2013 Category: Neurology Authors: Padua L, Granata G, Sabatelli M, Inghilleri M, Lucchetta M, Luigetti M, Coraci D, Martinoli C, Briani C Tags: Clin Neurophysiol Source Type: research

Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg
Conclusion: Patients with CIDP positive for IgG4 NF155 antibodies constitute a specific subgroup with a severe phenotype, poor response to IVIg, and disabling tremor. Autoantibodies against paranodal structures associate with distinct clinical features in CIDP and their identification has diagnostic, prognostic, and therapeutic implications. Classification of evidence: This study provides Class IV evidence that autoantibodies to NF155 identify a CIDP subtype characterized by severe neuropathy, poor response to IVIg, and disabling tremor.
Source: Neurology - March 10, 2014 Category: Neurology Authors: Querol, L., Nogales-Gadea, G., Rojas-Garcia, R., Diaz-Manera, J., Pardo, J., Ortega-Moreno, A., Sedano, M. J., Gallardo, E., Berciano, J., Blesa, R., Dalmau, J., Illa, I. Tags: ARTICLE Source Type: research